Shiv Rao
That's why Rao, a practicing cardiologist at the University of Pittsburgh Medical Center with an interest in machine learning, founded Abridge, which uses AI to turn doctors' conversations with patients into billable clinical notes that are integrated directly into health records. The tool works by recording a patient's visit (with their consent), automatically transcribing it, and creating a useful summary. 'Abridge unburdens clinicians from the clerical work that crushes their souls, so they can focus on the person in front of them,' says CEO Rao.
Abridge is now used at more than 100 health systems across the U.S., including Kaiser Permanente, Duke Health, Johns Hopkins Medicine, and UChicago Medicine. Rao expects that growth to continue: In February, the company raised $250 million, which it will funnel into research and development. It also started rolling out a product built for nurses at the Mayo Clinic in Arizona. The same month, a study published in the Journal of the American Medical Informatics Association concluded that 67% of clinicians using Abridge believed their risk of burnout due to paperwork had decreased, and 77% felt the tool improved patient care.
Rao recalls a rural primary care physician who wrote to the company about her experience with the tool. When she sat down to dinner with her family, her young son asked her: 'Mommy, why aren't you working right now?' The woman explained that she was using Abridge, a tool that allowed her to come home early enough for dinner—and that now, she could do so every night. 'Clinicians across the country can get their life back,' Rao says. 'But they can also hopefully deliver more empathetic care because they're more present and building better relationships.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 days ago
- Business Insider
$5.3 billion Abridge wants to make acquisitions. Here's what the healthcare AI startup is looking for.
Abridge is on a hot streak. Now, as the healthcare startup competes in the AI talent wars, it's preparing to go on a shopping spree. Abridge, which builds AI-powered software to transcribe and summarize patient-doctor conversations, landed a $300 million round in June led by Andreessen Horowitz. It was its second mega-raise in four months; the company had raked in a $250 million round in February. In 18 months, Abridge has raised $700 million in total and boosted its valuation from $850 million to $5.3 billion. Abridge CEO and cofounder Dr. Shiv Rao has big plans for all of that capital, he told Business Insider. "We've got a lot of money in the bank, and we want to spend 80% of it just going deeper, and expanding from connecting conversations to clinical notes into claims, clinical decision support, and care management," he said. With 80% of its cash reserved for doubling down on its tech, Abridge is earmarking the remaining 20% for potential acquisitions, Rao said. Those deals are looking increasingly critical in the brutal, competitive landscape of ambient healthcare scribes. Perhaps the most gutting release is set to come from Epic, the electronic health record giant that first partnered with Abridge back in 2023 in a watershed moment for the startup. Epic is now gearing up to launch an AI scribe of its own, Politico reported this month. Abridge declined to comment on the reports. Epic didn't respond to requests for comment. Epic's launch would follow healthcare startup Ambience, Abridge's biggest direct competitor, raising its own mega-round this summer. Ambience's $250 million Series C was co-led by Oak HC/FT and A16z, a longtime investor in Ambience that appears to be double-dipping in AI scribing with its growth investment in Abridge. And, as Abridge works to expand beyond scribing to use AI for tasks like processing medical bills, it's running up against private equity firms like New Mountain Capital pouring billions into their healthcare AI plays. Abridge has remained a frontrunner as the pressure builds. It's now working with over 150 large health systems, Rao said. The startup is also partnering closely with some of those health systems on its new products — Abridge said Tuesday it's collaborating with Pittsburgh health system Highmark Health on tech to automate prior authorization requests. And Abridge is focusing squarely on the patient-provider conversation as the starting point for each of its new tools or acquisition targets, Rao said. "The last thing we want to do is to become a company that's opening up a trench coat and selling you random things that have no coherence to our mission," he said. "But if there are things that are absolutely on our road map, it would be smart for us to have open ears." Eyeing fresh talent and tech As San Francisco-based Abridge has landed fundraise after fundraise, many startups hoping to get acquired by Abridge have entered Rao's inbox. While Rao said Abridge isn't "in talks" with any particular company, it's prepared to notch deals to grow faster. The startup hasn't made any acquisitions since its 2018 founding. "It feels like a lot of companies are asking if they can join us in some way. We need to be able to spend on things like that — data plays, ecosystem plays, and partnerships," Rao said. Acquiring top talent is Abridge's biggest priority, Rao said, adding that the startup has been competing with AI giants like OpenAI and Anthropic in its recent hiring efforts. The AI talent wars are raising the stakes for startups like Abridge. As Big Tech companies fight over top AI researchers, including by offering pay packages in the millions or tens of millions, startups are touting their mission-centric approaches to convince engineers to join their teams over tech giants. Rao thinks Abridge can compete effectively for AI talent by offering hires the rare chance to build tools that matter, tech that actually improves people's health. "Finding ways to recruit more world-class talent as fast as possible is really, really important for us," he said. "If this is the legacy you want to leave, if you want to be a part of a company where every single day you can feel really good that you improved patient care, then we're going to resonate more than those horizontal technology companies." Abridge has about 330 employees, a number Rao is aiming to increase massively, especially in its engineering department, though he says the company won't rely exclusively on M&A to do that. Abridge builds its own large-language models that its widening suite of software sits upon. Those models make up its "contextual reasoning engine," which automates clinical notetaking that can combine ambient scribing with relevant context from the patient's existing health records and generate actionable outputs like medical orders and suggested billing codes. Rao said Abridge is considering buying data where necessary to continue training its models. With a combination build-and-buy strategy, Abridge is moving further into revenue cycle management, the hottest ticket item in healthcare AI, since it aims to help health systems capture more revenue while saving time for doctors. Rao said Abridge is also working on areas like risk adjustment, the process of estimating a patient's expected medical costs, that is critical for value-based care arrangements, and care coordination. Abridge wants to dig deeper into clinical decision support, too, a field that many healthcare startups have stayed away from, as the tech often walks a thin line to avoid facing FDA regulations. Abridge first stepped into the space in October by partnering with medical insights company UpToDate to surface relevant clinical evidence in Abridge's generated notes. Rao said he expects Abridge to share more information from the partnership later this year. As Abridge looks to take over more tasks for doctors, the company is being deliberate about how and when it'll meet "good friction" like FDA regulation, Rao said. "As we move into higher-stakes workflows from a patient outcomes perspective, we have to be really, really responsible," he said. "We try to be as transparent as we possibly can on how our models work and how we evaluate them. We'll need to continue to be transparent as we get into those new spaces."
Business Insider
4 days ago
- Business Insider
'Q2T3' is the 'freakish' new growth benchmark for AI startups
A new growth metric is doing the rounds in Silicon Valley that shows how exuberant investors have become about generative AI. In a new State of AI 2025 report, Bessemer Venture Partners introduced a growth benchmark that sets a high bar for today's AI startup ecosystem. Called Q2T3 — short for quadruple, quadruple, triple, triple, triple — this metric signals a dramatic departure from the SaaS era's more measured growth expectations, typified by the "T2D3"—triple, triple, double, double, double— playbook. "We share these admittedly freakish new benchmarks to showcase the reality of standout AI startups of the moment," Bessemer wrote. Bessemer didn't name any specific startups. However, the firm said that it came up with this new metric by studying 20 high-growth, durable AI startups across its portfolio and beyond, including Abridge and Cursor. Escalating Expectations Bessemer usually releases a "State of the Cloud" report each year. This year, the VC firm changed it to the "State of AI," a sign of how much generative AI is changing the tech industry, upending cloud computing, and pressuring established software business models. T2D3 became the north star for SaaS startups during the last decade. This metric required startups to triple their annualized recurring revenue in the first year, then do it again in their second year. Then, they had to double ARR in the third year, and repeat that feat in years four and five. In theory, this would get ARR from $1 million or $2 million to more than $100 million in about five or six years — enough to earn a potential valuation of $1 billion. Bessemer thinks T2D3 is now being rapidly eclipsed by AI-native companies, which are demonstrating unprecedented velocity thanks to generative AI's unique dynamics: rapid product cycles, explosive user demand, and new distribution channels. Enter Q2T3, a far more aggressive trajectory. The new benchmark reflects a faster path where AI startups quadruple revenue in years one and two, and triple ARR in each of the next three years, according to Bessemer. This implies growing ARR from $3 million to more than $100 million in just four years, and then more after that — a feat that redefines what hypergrowth means in a post-ChatGPT world. "Shooting Stars" vs "Supernovas" Bessemer's Q2T3 model is based on a new archetype it calls "Shooting Stars." These are AI startups that grow meaningfully faster than SaaS counterparts, while maintaining capital efficiency, solid gross margins (~60%), and strong product-market fit. According to Bessemer, these startups achieve roughly $3 million ARR in their first year of monetization and about $164,000 in ARR per employee. Some AI startups are growing even faster, hitting $100 million in ARR in about 1.5 years. Bessemer calls these "Supernova" startups. "These are at once the most exciting and the most terrifying startups we see," the venture capital firm wrote in its report. These numbers often come from situations where revenue may be fragile, driven by rapid adoption that may not reflect lasting value. Low switching costs, highly competitive markets, and thinly differentiated products can push profit margins toward zero or below, Bessemer warned. In contrast, Shooting Stars find product-market fit quickly, retain and expand customer relationships, and maintain strong gross margins—slightly lower than SaaS peers due to faster growth and modest model-related costs. They grow faster on average than their SaaS predecessors, but at rates that still feel anchored to traditional bottlenecks of scaling an organization. "These businesses might not yet dominate headlines, but they're beloved by their customers and are on the trajectory to making software history," Bessemer wrote. "Freakish" but achievable While Q2T3 seems "freakish," the firm said it's not impossible for AI startups to attain. Generative AI has drastically compressed time-to-market, with faster development, deployment, and go-to-market cycles, and Bessemer argues that dozens of startups are already proving this curve is within reach. Still, Q2T3 isn't for the faint-hearted. Is it a new way to redefine startup success, or a sign of AI frothiness? Only time will tell.
Boston Globe
6 days ago
- Boston Globe
At least one dead in explosion at US Steel plant, authorities say
Joshua Pershing, a fourth-generation steelworker who works at the plant, said he was in another building at the plant and felt it shake from the blasts. Advertisement 'Next thing I knew, guys were running in, saying something just blew up,' said Pershing, 31. 'We don't know who's alive and who's gone,' he said, choking up. 'But pray for their families.' Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Few details were available on the extent of injuries or what caused the explosion near the northern end of the Clairton plant, a sprawling facility covering hundreds of acres along a mile-long bend of the Monongahela River, about 15 miles southeast of downtown Pittsburgh. Scott Buckiso, an executive vice president and chief manufacturing officer of US Steel, said the explosion happened at two coke oven batteries that had appeared to be in good condition before the blast. 'Safety is our No. 1 priority every day, every shift, 365,' Buckiso said. 'So, obviously, this is a tragedy that we want to understand.' Advertisement Earlier in the day, officials had estimated that dozens of people had been hurt. Abigail Gardner, a spokesperson for Allegheny County, said some people at the plant had been critically injured while others had minor wounds. The county health department urged people within 1 mile of the explosion to remain indoors. Ronnie Fordyce, who works at the plant, said he and others were on their lunch break, far away from where the explosions occurred, when they felt the blasts. 'Then we went outside and saw the smoke,' he said. Zachary Buday, a construction worker at a job site less than half a mile away from the plant, said the explosion 'took the air out of your chest,' even at a distance. A spokesperson for the Allegheny Health Network said that two of its trauma center hospitals had received one patient each. Five more patients were taken to the network's hospital that is closest to the scene, and all were released within a few hours. Three additional patients were taken to the University of Pittsburgh Medical Center. Butch Michaels, who works at Hometown Burgers and Deli next to the plant, said he felt the building shake and thought at first that it was from a construction site next to the deli. But his manager told him the blast was too strong for that. 'It blew our front door open,' Michaels said. Bernie Hall, who leads the United Steelworkers union in Pennsylvania, said in a statement that the union would seek a 'thorough investigation' and provide its members with support. The Allegheny County Police Department said its homicide unit would be leading the investigation with help from the county fire marshal and federal authorities. Advertisement The plant, which has been in operation for more than a century, is a remnant of the industrial concentration that built Pittsburgh into the Steel City and helped power the Industrial Revolution. Coal arrives at the plant by train and barge, and is converted into coke to fuel the blast furnaces that manufacture steel. US Steel said in a statement that the company was working with authorities to determine what had caused the disaster. 'Nearly 1,300 dedicated men and women work at the Clairton Plant each day, performing their jobs with the utmost safety,' David B. Burritt, the company's president, said in the statement. 'During times like this, US Steel employees come together to extend their love, prayers and support to everyone affected.' The company's website says that the plant is the largest coke manufacturing facility in the United States, with 10 operating batteries of coke ovens that produce a total of approximately 4.3 million tons of coke annually, according to US Steel. In recent years, the Clairton plant has drawn criticism from environmental groups and nearby residents over pollution and over what critics said was deficient maintenance. A sprinkler pipe failure in 2018 led to a fire at the plant on Christmas Eve, and there were power outages at the plant in 2019 and 2022. US Steel reached a settlement with Allegheny County and two environmental groups in 2024 in which the company agreed to pay $4.5 million toward environmental projects as a result of those incidents. The company also promised to invest roughly $19.5 million to upgrade its coke oven gas cleaning facilities. Richard Lattanzi, the mayor of Clairton, worked at US Steel for 30 years, including eight as a safety inspector, and said he knew it was a dangerous place to work. Advertisement But, he added, 'nobody should die at work.' He said he had met with workers at the plant. 'I shook all their hands,' he said. 'They're going to take it home with them.' Senator John Fetterman, Democrat of Pennsylvania, told reporters Monday that the disaster 'reminds everybody how dangerous of a job it is to make steel here.' 'It's just absolutely tragic,' he said. This article originally appeared in
